Literature DB >> 26864109

Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.

Tomoyuki Igawa1, Kenta Haraya2, Kunihiro Hattori1.   

Abstract

Monoclonal antibodies have become a general modality in therapeutic development, and a variety of monoclonal antibodies targeting soluble antigens have been developed. However, even with infinite binding affinity to an antigen, a conventional antibody can bind to the antigen only once and results in an increase in total plasma antigen concentration in vivo. This antibody-mediated antigen accumulation generally occurs because the clearance from circulation of an antibody-antigen complex is much slower than that of a free antigen. This limitation has recently been overcome by sweeping antibodies, which are capable of actively eliminating soluble antigens from circulation. A sweeping antibody incorporates two antibody engineering technologies: one is variable region engineering to enable the antibody to bind to an antigen in plasma and dissociate from the antigen in endosome (after which the antigen undergoes lysosomal degradation), and the other is constant region engineering to increase the cellular uptake of the antibody-antigen complex into endosome. By enhancing the elimination of soluble antigens from circulation, sweeping antibodies can therapeutically target soluble antigens that conventional antibodies cannot. This review discusses the features, engineering technologies, advantages, and applications of sweeping antibodies that target soluble antigens.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords:  FcRn; FcγRIIb; pH-dependent antigen-binding antibody; sweeping antibody

Mesh:

Substances:

Year:  2016        PMID: 26864109     DOI: 10.1111/imr.12392

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  30 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Authors:  Félicien Le Louedec; Catherine Alix-Panabières; Thierry Lafont; Ben C Allal; Renaud Garrel; Laurence Digue; Joël Guigay; Didier Cupissol; Jean-Pierre Delord; Benjamin Lallemant; Marc Alfonsi; Karine Aubry; Martine Mazel; François Becher; Françoise Perriard; Etienne Chatelut; Fabienne Thomas
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

Review 3.  Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.

Authors:  Masaru Ishii
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 4.  Research progress on neonatal Fc receptor and its application.

Authors:  Mangsha Hu; Shuli Wei; Wuyuan Zhou; Pingli Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

Review 5.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

6.  Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.

Authors:  Kenta Haraya; Tatsuhiko Tachibana
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

7.  Lysosome-targeting chimaeras for degradation of extracellular proteins.

Authors:  Steven M Banik; Kayvon Pedram; Simon Wisnovsky; Green Ahn; Nicholas M Riley; Carolyn R Bertozzi
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

Review 8.  Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway.

Authors:  Green Ahn; Steven M Banik; Carolyn R Bertozzi
Journal:  Cell Chem Biol       Date:  2021-03-25       Impact factor: 9.039

Review 9.  The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control.

Authors:  Roberta Lucchi; Jordi Bentanachs; Benjamí Oller-Salvia
Journal:  ACS Cent Sci       Date:  2021-04-26       Impact factor: 14.553

Review 10.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.